New oral GLP-1RA orforglipron comparable to semaglutide for weight loss

Written by | 22 Apr 2025 | Medicines and Therapeutics

Results from the ACHIEVE-1 trial show that treatment with orforglipron was associated with weight loss ranging from 4.7 – 7.9% (4.4 – 7.3 Kg) of body weight in obese, diabetic patients. Orforglipron is the first oral, small molecule (non-peptide), glucagon-like peptide-1 receptor agonist (GLP-1RA). The trial was designed to evaluate the safety and efficacy of orforglipron compared with placebo in adults with type 2 diabetes and inadequate glycaemic control with diet and exercise alone.

Key points 

  • The trial included 559 participants randomised in 1:1:1:1 ratio to receive 3 mg, 12 mg or 36 mg orforglipron or placebo.  All participants in the orforglipron treatment arms started the study at a dose of orforglipron 1 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomised maintenance dose.
  • The primary endpoint of the trial – a reduction of haemoglobin A1C – was achieved, with an average reduction of 1.3 – 1.6% from a baseline of 8%.
  • Weight loss was a secondary endpoint. Participants in this 40-week trial had not reached a weight plateau by the end of the trial, leading researchers to suggest that further weight loss may be possible.
  • The overall safety profile for orforglipron was comparable to other, established GLP-1RAs. The most common side effect was diarrhoea (affecting up to 26% of participants), followed by dyspepsia, constipation and vomiting. No hepatic safety signal was observed. (Note – April 14th, 2025 Pfizer announced discontinuation of development of danuglipron because of drug-induced liver injury.)
  • The full results of the ACHIEVE-1 trial will be presented at the forthcoming American Diabetic Association meeting in June 2025 and will be published in a peer-reviewed journal. (Note – The ATTAIN-1 trial is investigating the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.)

Orforglipron

Orforglipron is an orally bioavailable, non-peptide agonist of the GLP-1 receptor.

Unlike oral semaglutide (Rybelsus; Novo-Nordisk) It can be taken at any time of the day without restrictions on food or water intake. (Note – Rybelsus is approved for treatment of type 2 diabetes but not for weight management.)

In addition to studies for treatment of type 2 diabetes and weight management, orforglipron is also being studied as a potential treatment for obstructive sleep apnoea and hypertension in adults with obesity.

Lilly plans to seek approval for orforglipron for obesity later in 2025.

Interpretation

An oral GLP-1RA could fill an important gap in the market place – for many people a daily tablet is preferable to a weekly injection. Orforglipron might also find a place as a follow-on treatment for people who started their weight management with injectable semaglutide.

Two other major advantages of oforglipron are the relative ease of manufacturing a small molecule, compared to large molecular weight peptides, and easier storage and transport requirements (no refrigeration and less bulk).

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.